ITK/CRBN axis: Molecular tools for T-cell signaling regulation and targeted protein degradation

ITK is a core non-receptor tyrosine kinase in the T cell receptor (TCR) signaling pathway, regulating T cell subset differentiation by controlling PLCγ1 activation and calcium signal intensity. CRBN is the substrate-recognition subunit of the CRL4 E3 ubiquitin ligase complex, which can be bound by thalidomide-like small molecules to alter substrate specificity. PROTAC molecules designed based on CRBN ligands can induce ITK ubiquitination and proteasomal degradation, providing a research tool for eliminating ITK protein at the cellular level. This article reviews the molecular structures and signaling functions of ITK and CRBN, the principles of PROTAC technology, and the research progress of ITK/CRBN PROTAC, with a focus on its applications in cell biology research and the technical challenges it faces.

1.1 Molecular Structure

Interleukin-2-inducible T-cell kinase (ITK) belongs to the Tec family of non-receptor tyrosine kinases and is primarily expressed in T cells, natural killer cells, and mast cells. The amino acid sequence of ITK, from the N-terminus to the C-terminus, includes: a pleckstrin homology (PH) domain, a Tec homology (TH) domain (containing a proline-rich motif), an SRC homology 3 (SH3) domain, an SH2 domain, and a C-terminal kinase domain. The PH domain specifically binds phosphatidylinositol-3,4,5-trisphosphate, mediating ITK recruitment to the cell membrane upon TCR activation. The proline-rich motif in the TH domain can interact intramolecularly or intermolecularly with the SH3 domain or other signaling proteins, regulating ITK's intrinsic activity. The SH2 domain recognizes phosphorylated tyrosine motifs, anchoring ITK to activated signaling complexes. The kinase domain is the catalytic center for substrate tyrosine phosphorylation.

1.2 Functional Role in TCR Signal Transduction

Upon TCR recognition of peptide-MHC complexes on antigen-presenting cells, Lck kinase first phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 complex chains, recruiting and activating ZAP-70. Activated ZAP-70 phosphorylates multiple tyrosine residues on ITK, with phosphorylation at Y511 (located in the activation loop of the kinase domain) being critical for full ITK kinase activity. Activated ITK further phosphorylates residues Y783, Y775, and Y1253 on phospholipase C-γ1 (PLCγ1), activating its hydrolytic function. PLCγ1 hydrolyzes phosphatidylinositol-4,5-bisphosphate to generate two second messengers—inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ binds IP₃ receptors on the endoplasmic reticulum, triggering calcium ion release into the cytoplasm, while DAG binds effector proteins like protein kinase Cθ (PKCθ), initiating downstream signaling cascades. Elevated cytoplasmic calcium levels activate calcineurin, which dephosphorylates nuclear factor of activated T cells (NFAT), enabling its nuclear translocation. Meanwhile, PKCθ activates the IκB kinase (IKK) complex via the CARMA1-BCL10-MALT1 complex, leading to IκB phosphorylation and NF-κB transcription factor release. DAG can also activate the Ras-ERK pathway via RasGRP, ultimately driving AP-1 transcriptional activity. The coordinated action of NFAT, NF-κB, and AP-1 pathways regulates T cell proliferation, cytokine gene transcription, and metabolic reprogramming.

1.3 ITK and CD4⁺ T Cell Subset Differentiation

ITK signaling intensity influences the differentiation direction of naïve CD4⁺ T cells. A 2024 study published in Science Signaling reported that under conditions typically inducing Th17 polarization, naïve CD4⁺ T cells lacking ITK activity did not differentiate into Th17 cells but instead expressed Foxp3 and exhibited a regulatory T cell (Treg)-like phenotype. Mechanistic studies revealed that this differentiation shift primarily depended on ITK-regulated calcium signaling rather than the MAPK pathway. Reduced ITK activity altered the NFAT-dependent gene expression profile, suppressing induction of the Th17 lineage-specific transcription factor RORγt while permitting Foxp3 induction. Additionally, ITK deficiency or inhibition altered T cell metabolic states, reducing mitochondrial oxidative phosphorylation and glycolysis-related gene expression, aligning more closely with iTreg metabolic characteristics. These findings suggest ITK acts as a "signal rheostat" in T cells, with its activity intensity directly influencing lineage differentiation outcomes.

2.1 Assembly of the CRL4-CRBN Complex

Cereblon (CRBN) is the substrate-recognition component of the CRL4 E3 ubiquitin ligase complex. The core scaffold of this complex consists of cullin 4A or 4B (CUL4A/B), with the N-terminus of CUL4 binding the RING finger protein ROC1 (which recruits E2 ubiquitin-conjugating enzymes) and the C-terminus linking to CRBN via the adaptor protein DDB1. CRBN directly binds the C-terminal domain of DDB1, forming a CUL4-DDB1-CRBN quaternary complex. CRBN recognizes specific substrate proteins and presents them to adjacent E2 enzymes, initiating polyubiquitin chain synthesis.

2.2 Small Molecule Ligand Binding Properties

The C-terminal domain of CRBN contains a deep hydrophobic pocket that binds thalidomide and its structural analogs (e.g., lenalidomide, pomalidomide). Crystal structure analyses show that the glutarimide ring of thalidomide inserts into CRBN's hydrophobic pocket, forming hydrogen bonds and hydrophobic interactions with multiple amino acid residues. This binding event alters the substrate-recognition interface of the CRL4-CRBN complex, inducing ubiquitination of proteins not normally recognized—such as IKZF1 and IKZF3. This mechanism explains some cellular effects of immunomodulatory small molecules. Leveraging this property, CRBN ligands are widely used as E3-recruiting modules in PROTAC molecules.

2.3 CRBN's Regulation of Signaling Proteins

Beyond serving as a receptor for exogenous small molecules, CRBN itself participates in the homeostasis regulation of certain endogenous proteins. Studies show that CRBN catalyzes the ubiquitination and degradation of the proto-oncoprotein c-Jun, a core component of the activator protein-1 (AP-1) transcription complex. AP-1 plays a role in gene expression regulation downstream of TCR activation. Thus, CRBN abundance and activity may indirectly modulate AP-1-dependent transcriptional output by influencing c-Jun degradation rates. Additionally, CRBN expression levels vary across cell types and physiological states, with CpG island methylation in its promoter region negatively correlating with CRBN protein levels. This expression heterogeneity may affect the efficacy of CRBN-dependent small-molecule tools in different cellular models.

3.1 Basic Principles of PROTAC

Proteolysis-targeting chimeras (PROTACs) are synthetic heterobifunctional small molecules. Each PROTAC consists of three structural units: a target protein-binding ligand, an E3 ubiquitin ligase-recruiting ligand, and a chemical linker connecting the two. PROTACs simultaneously bind the target protein and E3 ligase in cells, bringing them into proximity (~10–20 Å). The E3 ligase then polyubiquitinates the neighboring target protein, forming ubiquitin chains (primarily K48-linked) of at least four ubiquitin monomers. Polyubiquitinated targets are recognized by the 26S proteasome and degraded into short peptides via ATP-dependent catalysis. Unlike traditional occupancy-driven inhibitors, PROTACs operate via an event-driven catalytic mechanism: a single PROTAC molecule can sequentially bind and degrade multiple target proteins before recycling. This catalytic property enables PROTACs to induce sustained protein knockdown at concentrations far below their binding affinity.

3.2 CRBN as an E3-Recruiting Module for PROTACs

Among the dozen E3 ligases used in PROTAC design, CRBN-based systems are the most widely applied. Common CRBN ligands include thalidomide, lenalidomide, pomalidomide, and structurally modified derivatives (e.g., 5-fluorothalidomide, 4-hydroxythalidomide). CRBN ligands offer advantages such as relatively small molecular weight (~250–300 Da), high synthetic feasibility, and nanomolar-to-micromolar binding affinity to CRBN. CRBN-based PROTACs typically have total molecular weights of 700–1000 Da, with comparatively higher cell permeability. However, endogenous CRBN expression levels vary across cell types—e.g., fluctuations in certain T cell lines or primary T cells—which may directly affect degradation efficiency. Experimental designs must pre-confirm CRBN expression in target cell models via immunoblotting or qPCR.

3.3 Research Progress on ITK/CRBN PROTACs

In 2023, researchers first reported the CRBN-recruiting ITK-specific degrader BSJ-05-037. This molecule uses an ATP-competitive ITK ligand as the target-binding head, a pomalidomide analog as the CRBN ligand, and a PEG-alkyl hybrid linker. In T cell lymphoma-derived DERL-2 and Hut78 cell lines, BSJ-05-037 achieved a DC₅₀ of 17.6–41.8 nM after 24 hours. Mechanistic validation showed: degradation was blocked by CRBN siRNA co-transfection; the NEDD8-activating enzyme inhibitor MLN4924 (which inactivates cullin family proteins by inhibiting neddylation) also abolished ITK degradation; and proteasome inhibitor MG132 treatment caused ubiquitinated ITK accumulation. These results confirmed CRL4-CRBN and proteasome dependence. Functionally, BSJ-05-037 reduced PLCγ1 Y783 phosphorylation, suppressed NF-κB reporter activity, and lowered IL-2 and IFN-γ transcription.

Subsequent structure-activity relationship studies optimized ITK PROTACs. ITK degrader 1 (Compound 28) used a shorter linker, reducing DC₅₀ to 3.6 nM in the same models. In mice, intraperitoneal injection (20 mg/kg) of ITK degrader 1 reduced splenic T cell ITK levels within 2 hours, lasting up to 16 hours. Further modifications yielded ITK degrader 2 (Compound 30), which replaced the CRBN ligand with 5-fluorothalidomide and optimized the piperidine-piperazine linker. ITK degrader 2 achieved DC₅₀ <10 nM and, crucially, showed detectable degradation activity after oral gavage (90 mg/kg): plasma C_max = 0.87 μM, T_max = 2 hours. This oral activity expands its potential for long-term protein knockdown studies in vivo.

Beyond selective ITK degraders, multitarget PROTACs with ITK activity have been reported. For example, TL12-186 degrades CDK, BTK, FLT3, Aurora kinases, and ITK, among others. PROTACs based on azaspirooxindole scaffolds can simultaneously target ITK and BTK. Such multitarget degraders are useful for studying kinase family functional redundancy but require careful controls (e.g., combinatorial single-target degraders or genetic knockout validation) to attribute specific phenotypes.

4.1 Molecular Physicochemical Properties and Cellular Delivery

PROTAC molecular weights often exceed Lipinski's Rule of Five guidelines (500 Da). High molecular weight and limited conformational rigidity reduce cell membrane permeability, sometimes requiring micromolar extracellular concentrations for sufficient intracellular accumulation. In primary T cells—with lower transfection efficiency and endocytic capacity than immortalized lines—PROTAC delivery is even more challenging. Linker length (typically 5–20 atoms), composition (PEG, alkyl chains, heterocycles), and flexibility significantly impact PROTAC conformation, solubility, permeability, and metabolic stability, making linker optimization central to improving cellular activity.

4.2 Degradation Selectivity Assessment

CRBN-based PROTACs may induce "neosubstrate" degradation independently of the target protein. Neosubstrates (e.g., IKZF1/3) are proteins degraded by CRL4-CRBN when thalidomide-like molecules are present alone. Thus, ITK/CRBN PROTACs could produce dual knockdown: intended ITK degradation and unintended IKZF1/3 degradation. Without proper controls (e.g., CRBN-binding-deficient PROTACs or CRBN-knockout validation), phenotypes attributed to ITK degradation may conflate with IKZF1/3 contributions. Whether ITK degrader 2 induces IKZF1/3 degradation remains unreported. Global proteomic analysis (e.g., tandem mass tag-based quantitative proteomics) is the gold standard for unbiased selectivity assessment.

4.3 Cell Model Selection and Validation

Endogenous CRBN expression varies significantly across cell types. CpG island hypermethylation in the CRBN promoter silences transcription in many cancer cell lines. In CRBN-low/negative cells (e.g., certain Jurkat subclones or primary T cell samples), CRBN-based ITK PROTACs will fail. Thus, CRBN protein must be confirmed via immunoblotting before functional experiments. For CRBN-low cells, ITK PROTACs using alternative E3 ligases (e.g., VHL) are viable. Even with confirmed CRBN expression, degradation must be validated via CRBN silencing or ligand competition (excess free thalidomide/lenalidomide) to confirm CRBN dependence.

The ITK/CRBN PROTAC system integrates TCR signaling regulation with targeted protein degradation tools. ITK, as a core kinase in T cell calcium signaling, enables precise protein-level knockdown for studying its dose-dependent effects in Th17/Treg lineage commitment—surpassing genetic knockout. CRBN-based PROTACs have yielded oral-active tool compounds (BSJ-05-037, ITK degrader 1/2) with DC₅₀ <10 nM. Challenges—degradation selectivity, cell model dependency, and molecular optimization—are shared across the PROTAC field. Rigorous application of ITK/CRBN PROTACs with proper controls will clarify ITK's functional contributions to T cell signaling networks.

---